Medicus Pharma (NASDAQ: MDCX) Announces Teverelix Clinical Data Accepted for AACE 2026 Presentation

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Jan 12 2026

0mins

MDCX-2.7%

Should l Buy MDCX?

Source: Globenewswire

Clinical Data Acceptance: Medicus Pharma's Teverelix clinical data has been accepted for presentation at the AACE 2026 Annual Meeting, marking a significant recognition in the biopharmaceutical field that could enhance investor confidence.
Significant Trial Results: In two randomized controlled Phase I studies, 48 healthy women receiving Teverelix injections showed rapid suppression of LH and FSH within 24 hours, indicating the drug's potential in women's health, particularly for endometriosis treatment.
Favorable Safety Profile: The results demonstrated that Teverelix maintained stable bone turnover markers without evidence of short-term bone loss, enhancing its safety for clinical use and potentially attracting more strategic partnerships.
Strategic Development Focus: Medicus plans to conduct a Phase 2 study of Teverelix in the UAE, aiming to further validate its application in women's health, showcasing the company's emphasis on emerging markets and strategic growth opportunities.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MDCX?" and start using high-conviction signals backed by rigorous historical data.

MDCX

$1.08+Infinity%1D

Analyst Views on MDCX

Wall Street analysts forecast MDCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDCX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.110

Low

12.00

Averages

12.00

High

12.00

Current: 1.110

Low

12.00

Averages

12.00

High

12.00

Brookline

Buy

upgrade

$12 -> $20

2025-09-24

Reason

Brookline

Price Target

$12 -> $20

AI Analysis

2025-09-24

upgrade

Buy

Reason

Brookline raised the firm's price target on Medicus Pharma to $20 from $12 and keeps a Buy rating on the shares. The firm is updating its model following completion of aquisition of Antev Limited. Medicus acquired 98.6% of Antev for $75M, which includes $2.97M in cash and 1,603,164 common shares of Medicus, plus $65M in contingent payments tied to potential future Teverelix Phase 2 trial data and New Drug Application approvals. Brookline is including the potential of Teverelix in Acute Urinary Retention in its model, but does not include the potential for Teverelix in prostate cancer in its model and expects to add it to the model following Phase 2 data.

D. Boral Capital

Jason Kolbert

Buy

maintain

$14 -> $27

2025-05-12

Reason

D. Boral Capital

Jason Kolbert

Price Target

$14 -> $27

2025-05-12

maintain

Buy

Reason

D. Boral Capital analyst Jason Kolbert raised the firm's price target on Medicus Pharma to $27 from $14 and keeps a Buy rating on the shares after the company signed a binding letter of intent to acquire Antev. This acquisition adds "significant strategic value" by bringing in Teverelix, a next-generation GnRH antagonist with strong clinical rationale and late-stage readiness, the analyst tells investors in a research note. The firm says Teverelix addresses two large, underserved markets - acute urinary retention recurrence prevention and advanced prostate cancer in patients with high cardiovascular risk. D. Boral views the transaction as a "savvy, de-risked pipeline expansion that materially enhances Medicus' near-commercial portfolio and positions the company for accelerated value creation."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MDCX

Unlock Now

About MDCX

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Medicus Pharma to Ring Nasdaq Opening Bell on January 22, 2026, Celebrating One-Year Anniversary

Jan 20 2026Globenewswire

Anniversary Celebration: Medicus Pharma will ring the Nasdaq Opening Bell on January 22, 2026, at the Nasdaq MarketSite in Times Square, New York, marking its one-year anniversary as a publicly listed company and highlighting its steady growth in the capital markets.
Significant Clinical Progress: The company is advancing two key therapeutic assets, SkinJect targeting basal cell carcinoma with an estimated $2 billion market opportunity, and Teverelix for high cardiovascular risk prostate cancer patients, representing a combined market potential of $6 billion, showcasing its strategic positioning in precision medicine.
Clinical Trial Advancements: Medicus has successfully enrolled 90 patients in the Phase 2 clinical trial for SkinJect in the U.S., with topline results expected in Q1 2026, which will lay the groundwork for future partnership opportunities and enhance the company's influence in the biopharmaceutical sector.
Strategic Collaboration Expansion: The company has entered a non-binding letter of intent with Reliant AI Inc. to develop an AI-driven clinical data analytics platform aimed at improving capital-efficient clinical development, expected to support an upcoming Teverelix clinical study planned for 2026.

Medicus Pharma Rings Nasdaq Opening Bell to Celebrate One-Year Listing Anniversary

Jan 20 2026Newsfilter

Anniversary Celebration: Medicus Pharma will ring the Nasdaq Opening Bell on January 22, 2026, in Times Square, New York, marking its one-year anniversary as a public company, reflecting its stability and growth potential in the capital markets.
Clinical Development Progress: The company is focused on advancing key therapeutic assets like SkinJect and Teverelix, with SkinJect targeting a $2 billion market opportunity for basal cell carcinoma and Teverelix addressing high cardiovascular risk in prostate cancer patients, collectively representing a $6 billion commercial value.
Clinical Trial Results: The Phase 2 trial for SkinJect is nearing completion of patient enrollment, with topline results expected in Q1 2026, potentially creating partnership opportunities and further enhancing the company's influence in the biotech sector.
Strategic Collaboration and Expansion: The partnership with the Gorlin Syndrome Alliance aims to provide expanded access to SkinJect for patients with multiple basal cell carcinomas, expected to gather crucial safety and tolerability data, thereby strengthening the company's market position in rare diseases.